Simulations Plus Invests in Clinical Development Technology Company Nurocor
Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies through digitalization in the clinical development phase. Its solution significantly accelerates the typical clinical trial lifecycle, resulting in a reduction of the overall cost of the clinical development process.
The investment was made as part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage technology companies accelerating innovations within the pharmaceutical industry.
'We are pleased to support Nurocor in its mission to help clients leverage technology to bring drugs to market more rapidly,' said Shawn O'Connor, Chief Executive Officer of Simulations Plus. 'Their vision aligns with our own, and we see tremendous potential for clients to deploy our complementary solutions in clinical trial design, protocol development, and site competency and compliance. We believe our investment in Nurocor will deliver considerable and measurable value to clients and ultimately get much-needed treatments to patients faster.'
'We are excited to make this strategic investment through our Corporate Development Initiative,' said Will Frederick, Chief Financial Officer of Simulations Plus. 'This initiative is specifically designed to foster growth for early-stage companies, as well as identify potential partners and acquisition targets that complement our organic growth strategy and expand our total addressable market.'
In 2024, the clinical trial technology and services sector—which encompasses digital tools and services—was estimated at $25.7 billion. It is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030, driven by the increasing adoption of digital health technologies and the growing demand for more efficient patient recruitment.
'We are thrilled to have the support of Simulations Plus as we enter our next stage of growth,' said Alex Lazar, Chief Executive Officer of Nurocor. 'The investment is a strong vote of confidence in our team and technology, and we look forward to partnering with them to help clients realize efficiencies through the optimization and automation of their clinical trials.'
Interested parties can learn more about Simulations Plus' Corporate Development Initiative here.
About Simulations Plus, Inc.
With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update.
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. ###
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Cineverse Adds Three Industry Veterans to Accelerate Feature Film Acquisitions and Releasing Business
New Cineverse Motion Pictures Group Brings Key Talent on Board: Steven Peros as VP, Creative Development and Filmmaker Relations; Dan Fisher as VP, Acquisitions; and Cameron Moore as Consultant, Theatrical Distribution LOS ANGELES, July 15, 2025 /PRNewswire/ -- Cineverse (Nasdaq: CNVS), a next-generation entertainment studio, has announced today the addition of three development, acquisitions and distributions experts to the recently-formed Cineverse Motion Pictures Group led by Chief Motion Pictures Officer Yolanda Macias. Effective immediately: Steven Peros is vice president, creative development and filmmaker relations, responsible for both leading development and overseeing physical production, serving as a key connector between the creative community and internal business stakeholders. Peros started in development at New Line Cinema and was the William Morris Agency's top story analyst before becoming a screenwriter, director, producer, playwright, published film historian and graphic novel author, including projects with Disney, Lifetime, Lionsgate, AMC, MTV and NBC. He has taught screenwriting and TV pilot writing at New York Film Academy and UCLA Extension. Dan Fisher is vice president, acquisitions, leading acquisitions for Cineverse's direct-to-digital and OTT slate. Prior to joining Cineverse, he has over a decade of acquisition, digital sales and distribution experience via roles at VMI Worldwide, Freestyle Digital Media, Gravitas Ventures and Entertainment One, and has taught film at universities around the country. Cameron Moore is a consultant for the theatrical distribution business, responsible for directly assisting in strategic planning for theatrical releases, while identifying new film projects to acquire. Moore previously served as senior director, theatrical distribution at Gravitas Ventures, where he oversaw the expansion of his department and contributed to wide releases of films across North America. He has spent his career generating revenues and maximizing profitability, including promotional effectiveness. He has worked at numerous companies including 21st Century Fox, Screenvision Media, and Fathom Events in the United States, in addition to Rogers Media and Alliance Films in Canada. "I'm thrilled to be adding these three talented executives, each with a unique set of skills and experience that will contribute to Cineverse successfully implementing our motion pictures strategy," said Macias. "As we build out our theatrical, digital and streaming slate, we are strongly positioned to identify fandoms to target with IP driven and award winning releases, and reach audiences in an authentic and efficient manner. Our mission is to deliver for fans, creators and partners." About Cineverse Motion Pictures Group Cineverse super-serves passionate audiences by distributing content across all windows and platforms, from theatrical to digital to physical. Following the breakout box office success of Terrifier 3, upcoming releases include the franchise expansions of The Toxic Avenger (August 29, 2025), Silent Night, Deadly Night (December 12, 2025), Return to Silent Hill (January 23, 2026), and Wolf Creek: Legacy (2026) as well as 2025 releases Escape from the 21st Century, Lesbian Space Princess, and The Things You Kill. About Cineverse Cineverse (Nasdaq: CNVS) is a next-generation entertainment studio that empowers creators and entertains fans with a wide breadth of content through the power of technology. It has developed a new blueprint for delivering entertainment experiences to passionate audiences and results for its partners with unprecedented efficiency, and distributes more than 71,000 premium films, series, and podcasts. Cineverse connects fans with bold, authentic, independent stories. Properties include the highest-grossing unrated film in U.S. history; dozens of streaming fandom channels; a premier podcast network; top horror destination Bloody Disgusting; and more. Powering visionary storytelling with cutting-edge innovation, Cineverse's proprietary streaming tools and AI technology drive revenue and reach to redefine the next era of entertainment. For more information, visit Press Contact: For MediaThe Lippin Group, cineverse@ For InvestorsJulie Milstead, investorrelations@ View original content to download multimedia: SOURCE Cineverse Corp. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Citigroup (C) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Citigroup (C) closed at $87.60, marking a -1.26% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. On the other hand, the Dow registered a loss of 0.94%, and the technology-centric Nasdaq decreased by 0.92%. Heading into today, shares of the U.S. bank had gained 13.37% over the past month, outpacing the Finance sector's gain of 4.61% and the S&P 500's gain of 5.22%. Investors will be eagerly watching for the performance of Citigroup in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 15, 2025. The company's earnings per share (EPS) are projected to be $1.67, reflecting a 9.87% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $20.93 billion, reflecting a 3.92% rise from the equivalent quarter last year. C's full-year Zacks Consensus Estimates are calling for earnings of $7.33 per share and revenue of $83.95 billion. These results would represent year-over-year changes of +23.19% and +3.47%, respectively. Investors should also take note of any recent adjustments to analyst estimates for Citigroup. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 1% fall in the Zacks Consensus EPS estimate. Right now, Citigroup possesses a Zacks Rank of #3 (Hold). In terms of valuation, Citigroup is currently trading at a Forward P/E ratio of 12.11. This valuation marks a discount compared to its industry average Forward P/E of 16.39. Investors should also note that C has a PEG ratio of 0.69 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Financial - Investment Bank industry had an average PEG ratio of 1.37. The Financial - Investment Bank industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 67, placing it within the top 28% of over 250 industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Citigroup Inc. (C) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
27 minutes ago
- Yahoo
Unsung AI stock pops after joining S&P 500
Unsung AI stock pops after joining S&P 500 originally appeared on TheStreet. Though smaller-cap indexes swung wildly, the S&P 500 has been a lot more confident, continuing to grind higher in 2025. Unsurprisingly, Big Tech is pulling its weight, and AI momentum has shown no signs of fading. 💵💰💰💵 That said, one rising AI stock just cleared a massive milestone, and it's quietly stepping onto a bigger stage that will usher in a new growth phase for its business. For companies, getting into the S&P 500 isn't just a flex; it's a monumental event. It's like hitting the jackpot, as you're not only thrown into the spotlight, but also unleashing billions in passive inflows from index funds. Once companies get the green light from the S&P Dow Jones Indices committee, it's game on, as traders, fund managers, and analysts don't wait need a minimum market cap of roughly $22.7 billion, robust liquidity (dollar volume to float above 0.75), and a minimum of 250,000 monthly trading volume. On top of that, companies need at least a 10% public float, a U.S. headquarters, a major exchange listing, and yes, genuine profits in the last quarter and over the past year. An S&P 500 inclusion doesn't just mean a stock bump for companies. It brings more analyst coverage, attractive corporate optics, and even a lower financing structure. In simple terms, the company hits the big leagues, which shows investors that the business has genuine staying power. The index is up 6.6% so far in 2025; it's comfortably outpaced the Dow, while tracking slightly behind the Nasdaq. Generative AI and tech giants are doing all the heavy lifting, but consumer names haven't dropped the ball, either. More Tech Stock News: Veteran analyst drops massive call on AMD stock Bank of America drops shocking call on Super Micro stock Cathie Wood drops bold message on Apple, Tesla stock Despite the inflationary pressures and Fed uncertainty, pullbacks have been mostly shallow. Dips get snapped up quickly by investors who are hunting for value in places such as health care and utilities. Compared to the chaos in smaller-cap names, the S&P's healthy rise feels much more reliable. That's exactly the backdrop one 'sleeper' stock just stepped into. The Trade Desk () just staked its claim to the S&P 500. Trade Desk stock surged 14% on Monday after the digital adtech platform was tapped to join the S&P 500. It replaced ANSYS ahead of its much-talked-about acquisition by Synopsys, with the move becoming official before markets open Friday, July 18. For investors, that upgrade means fresh new capital will be funneling into The Trade Desk, whether markets like it or not. The California-based company operates one of the most advanced AI-powered demand-side platforms (DSPs) in the market. The platform enables advertisers to buy across multiple digital channels, from mobile and desktop to streaming TV in real it gives brands full visibility into where every dollar goes, and users can efficiently target, measure, and optimize campaigns. The real kicker? AI. At the core of its platform is Koa, a tailor-made AI engine that crunches bid signals to predict which ads are likely to perform well. It doesn't just automate bidding — it adapts in real time to efficiently maximize return on investment. And it's not stopping there. The Trade Desk recently launched cutting-edge new tools in tracking viewer behavior across screens, partnering with the leading streaming platforms while rolling out privacy-first identity tech with Unified ID 2.0. What's amazing is that despite the sluggishness in the ad market, The Trade Desk is growing. And now, with its S&P 500 inclusion, it's now finally playing at a tremendous AI stock pops after joining S&P 500 first appeared on TheStreet on Jul 15, 2025 This story was originally reported by TheStreet on Jul 15, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
